Dr Laurence Cooper talks to ecancer at the 2013 ASH Annual Meeting in New Orleans about using a patient's T cells to target the specific antigen, CD19, to target malignant B cells. This process of gene therapy has a number of issues, including persistence and toxicity. Dr Cooper commented, "One...

Dr Gribben talks to ecancertv at ASH 2013 about a session covering the latest for CLL treatment. This session focused on recent advances in the management of chronic lymphocytic leukaemia (CLL). The most recent, targeted drugs for CLL, as well as therapeutic concepts for elderly, non-fit...

Acute promyelocytic leukaemia is a subtype of acute myeloid leukaemia. There has been great success using a chemotherapy free regimen of retinoic acid combined with arsenic trioxide. Dr Mazzarella also discusses chronic vs cure, risk factors such as obesity - which can also influence outcomes -...